Luke Evnin Sells 46,664 Shares of Werewolf Therapeutics (NASDAQ:HOWL) Stock

Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Director Luke Evnin sold 46,664 shares of Werewolf Therapeutics stock in a transaction that occurred on Monday, October 27th. The stock was sold at an average price of $1.72, for a total transaction of $80,262.08. Following the completion of the transaction, the director directly owned 4,263,196 shares in the company, valued at approximately $7,332,697.12. The trade was a 1.08% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

Luke Evnin also recently made the following trade(s):

• On Wednesday, October 29th, Luke Evnin sold 86,154 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $1.55, for a total transaction of $133,538.70.
• On Tuesday, October 28th, Luke Evnin sold 44,327 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $1.64, for a total transaction of $72,696.28.

Werewolf Therapeutics Price Performance

NASDAQ HOWL opened at $1.40 on Friday. The firm’s fifty day simple moving average is $1.62 and its two-hundred day simple moving average is $1.31. The firm has a market capitalization of $64.02 million, a P/E ratio of -0.85 and a beta of 0.76. The company has a current ratio of 5.30, a quick ratio of 5.30 and a debt-to-equity ratio of 0.60. Werewolf Therapeutics, Inc. has a 12-month low of $0.60 and a 12-month high of $2.75.

Werewolf Therapeutics (NASDAQ:HOWL) last posted its quarterly earnings data on Thursday, August 14th. The company reported ($0.40) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.50) by $0.10. Analysts forecast that Werewolf Therapeutics, Inc. will post -1.56 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of analysts recently commented on the stock. Zacks Research upgraded shares of Werewolf Therapeutics from a “hold” rating to a “strong-buy” rating in a research note on Thursday, October 16th. Citigroup restated a “buy” rating on shares of Werewolf Therapeutics in a research note on Monday, August 25th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Werewolf Therapeutics in a research report on Wednesday, October 8th. Bank of America dropped their price target on Werewolf Therapeutics from $9.00 to $8.00 and set a “buy” rating on the stock in a research note on Monday, August 25th. Finally, JMP Securities decreased their target price on Werewolf Therapeutics from $4.00 to $3.00 and set a “market outperform” rating for the company in a report on Thursday, August 21st. One investment analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Werewolf Therapeutics currently has an average rating of “Moderate Buy” and an average price target of $8.00.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the stock. MPM Asset Management LLC boosted its position in Werewolf Therapeutics by 0.6% in the 1st quarter. MPM Asset Management LLC now owns 4,309,860 shares of the company’s stock worth $4,189,000 after purchasing an additional 25,688 shares in the last quarter. MPM Bioimpact LLC lifted its stake in shares of Werewolf Therapeutics by 0.9% in the 1st quarter. MPM Bioimpact LLC now owns 2,408,810 shares of the company’s stock valued at $2,341,000 after purchasing an additional 20,799 shares during the period. Bank of America Corp DE boosted its holdings in Werewolf Therapeutics by 1.2% during the second quarter. Bank of America Corp DE now owns 2,129,024 shares of the company’s stock worth $2,321,000 after buying an additional 25,882 shares in the last quarter. Jane Street Group LLC acquired a new stake in Werewolf Therapeutics during the second quarter valued at $409,000. Finally, Marshall Wace LLP purchased a new position in Werewolf Therapeutics in the second quarter valued at $113,000. 64.84% of the stock is owned by institutional investors and hedge funds.

About Werewolf Therapeutics

Werewolf Therapeutics, Inc, a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies.